ir.ultragenyx.comInvestors | Ultragenyx Pharmaceutical Inc.
ir.ultragenyx.com Profile
Ir.ultragenyx.com is a subdomain of ultragenyx.com, which was created on 2010-03-12,making it 14 years ago.
Description：The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial...
Discover ir.ultragenyx.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.ultragenyx.com Information
| HomePage size: 66.556 KB |
| Page Load Time: 0.596837 Seconds |
| Website IP Address: 184.28.219.56 |
ir.ultragenyx.com Similar Website
| BioMarin Pharmaceutical Investor Relations |
| Maryland Real Estate Investors Association - Maryland Real Estate Investors Association |
| Teva Pharmaceutical Industries Ltd. - Investors |
| Western Midstream - Investors - Investors |
| Investors | Kidoz Inc. – Kidoz Inc. |
| OMNOVA Solutions - Investors - Investors |
| Investors | Marathon Oil Corporation - Investors |
| Pharmaceutical Supply, Pharmaceutical Manufacturing, Contract Research, Pharmaceutical Outsourcing |
| Axalta Coating Systems - Investors - Investors Overview |
| School of Pharmacy and Pharmaceutical Sciences - School of Pharmacy and Pharmaceutical Sciences - Un |
| Top Pharma Conferences | Pharmaceutical Sciences Conferences | Pharmaceutical Research Conferences 2 |
| Pharmaceutical Engineering Home | ISPE | International Society for Pharmaceutical Engineering |
| Connected Investors | Connect With Real Estate Investors |
| Investors - Toromont Industries Ltd. - Investors |
ir.ultragenyx.com PopUrls
| Investors & Media—Ultragenyx Pharmaceutical Inc. https://ir.ultragenyx.com/ |
| Unsubscribe https://ir.ultragenyx.com/unsubscribe |
| 0001564590-20-025088 | 8-K | XBRL Viewer https://ir.ultragenyx.com/node/12701/xbrl-viewer |
| 0000950170-23-000338 | 8-K | iXBRL Viewer https://ir.ultragenyx.com/node/15426/ixbrl-viewer |
| 0000950170-21-000408 | 8-K | iXBRL Viewer https://ir.ultragenyx.com/node/14101/ixbrl-viewer |
| 0001564590-19-033927 | 8-K | iXBRL Viewer https://ir.ultragenyx.com/node/12036/ixbrl-viewer |
| 0000950170-23-026375 | 8-K | XBRL Viewer https://ir.ultragenyx.com/node/15801/xbrl-viewer |
| 0000950170-22-005981 | 8-K | iXBRL Viewer https://ir.ultragenyx.com/node/14866/ixbrl-viewer |
| 0000950170-23-058240 | 8-K | XBRL Viewer https://ir.ultragenyx.com/node/16301/xbrl-viewer |
| Press releases—Ultragenyx Pharmaceutical Inc. https://ir.ultragenyx.com/press-releases |
| Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with ... https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-positive-interim-phase-12-data-patients |
| Stock information—Ultragenyx Pharmaceutical Inc. https://ir.ultragenyx.com/stock-information |
| Ultragenyx Reports First Quarter 2022 Financial Results and Corporate ... https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-reports-first-quarter-2022-financial-results-and |
| Ultragenyx and GeneTx Provide Program Update on GTX-102 for ... - Investors https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-genetx-provide-program-update-gtx-102-angelman |
| Ultragenyx Receives FDA Agreement to Expand Ongoing Global ... - Investors https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-receives-fda-agreement-expand-ongoing-global-phase-12 |
ir.ultragenyx.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1601694056" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Sat, 03 Oct 2020 03:00:56 GMT |
| Link: http://ir.ultragenyx.com/; rel="shortlink", http://ir.ultragenyx.com/; rel="canonical", https://ir.ultragenyx.com/investor-relations; rel="alternate"; hreflang="en", https://ir.ultragenyx.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Request-ID: v-a86c45e4-0524-11eb-a9c1-d3033608dd00 |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 11311 |
| X-EdgeConnect-MidMile-RTT: 50, 50 |
| X-EdgeConnect-Origin-MEX-Latency: 290, 290 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Sat, 03 Oct 2020 03:00:57 GMT |
| Date: Sat, 03 Oct 2020 03:00:57 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
| Strict-Transport-Security: max-age=15768000 ; preload |
ir.ultragenyx.com Meta Info
| charset="utf-8"/ |
| content="Ultragenyx Pharmaceutical Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="https://ir.ultragenyx.com/investor-relations" property="og:url"/ |
| content="Investors | Ultragenyx Pharmaceutical Inc." property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
ir.ultragenyx.com Ip Information
| Ip Country: United States |
| City Name: Cambridge |
| Latitude: 42.3603 |
| Longitude: -71.0818 |
ir.ultragenyx.com Html To Plain Text
Investors Investors Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Press Releases Date Title and Summary Toggle Summary Sep 25, 2020 Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit NOVATO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE)Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Toggle Summary Sep 3, 2020 Ultragenyx to Present at Upcoming Investor Conferences NOVATO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE)Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Toggle Summary Sep 2, 2020 Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer Ms. Dier will start in new role in November 2020 NOVATO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE)Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today View all press releases » Investors Investor Relations Press Releases Events & Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage Investor FAQ Contact Us Shareholder Tools Email Alerts Print Share Facebook Google LinkedIn Twitter RSS About Management Emil D. Kakkis, M.D., Ph.D. Jayson Dallas, M.D. Dennis Huang Thomas Kassberg Karah Parschauer John Pinion Shalini Sharp Board of Directors Daniel G. Welch Emil D. Kakkis, M.D., Ph.D. William Aliski Deborah Dunsire, M.D. Lars Ekman, M.D., Ph.D. Matthew K. Fust Michael Narachi Clay B. Siegall, Ph.D. Grants & Charitable Contributions Message from BIO Medicines Crysvita® Mepsevii™ Dojolvi™ Pipeline DTX 301 for OTC DTX 401 for GSDIa Presentations & Publications For Patients XLH TIO MPS 7 LC-FAOD OTC GSD1a Access to Approved Therapies Access to Investigational Therapies Investors Investors Press Releases Events & Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage Investor FAQ Contact Us Careers Culture Benefits Talent Network Jobs Partnering Current Partnerships Contact About Management Emil D. Kakkis, M.D., Ph.D. Jayson Dallas, M.D. Dennis Huang Thomas Kassberg Karah Parschauer John Pinion Shalini Sharp Board of Directors Daniel G. Welch Emil D. Kakkis, M.D., Ph.D. William Aliski Deborah Dunsire, M.D. Lars Ekman, M.D., Ph.D. Matthew K. Fust Michael Narachi Clay B. Siegall, Ph.D. Grants & Charitable Contributions Message from BIO Medicines Crysvita® Mepsevii™ Dojolvi™ Pipeline DTX 301 for OTC DTX 401 for GSDIa Presentations & Publications For Patients XLH TIO MPS 7 LC-FAOD OTC GSD1a Access to Approved Therapies Access to Investigational Therapies Investors Investors Press Releases Events & Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage Investor FAQ Contact Us Careers Culture Benefits Talent Network Jobs Partnering Current Partnerships Contact Driving Directions Privacy Policy © 2020 Ultragenyx Pharmaceutical Inc. Website Design : Hane Chow, Inc. Privacy Policy Cookie...
ir.ultragenyx.com Whois
Domain Name: ULTRAGENYX.COM Registry Domain ID: 1588559037_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.cloudflare.com Registrar URL: http://www.cloudflare.com Updated Date: 2021-04-26T04:21:18Z Creation Date: 2010-03-12T18:52:56Z Registry Expiry Date: 2027-07-27T11:59:59Z Registrar: CloudFlare, Inc. Registrar IANA ID: 1910 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: BARBARA.NS.CLOUDFLARE.COM Name Server: JOSE.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T20:54:26Z <<<